Drug Trial Radar · NCT06625671
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
148
Planned (sponsor's estimate)
Start
Oct 4, 2024
Primary completion
Jun 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- DualityBio Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus
Conditions
- Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
Interventions
DB-2304Drug
DB-2304
PlaceboDrug
Placebo
PrednisoneDrug
Prednisone
Primary outcomes
What the sponsor says the trial is designed to measure.
- TEAEsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
- SAEsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
- ECG parametersTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
- Weight measurementsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
- Heart Rate measurementsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
- Pulse rate measurementsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
- Respiratory rate measurementsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
- Body temperature measurementsTime frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
US06-0
La Palma, California · Recruiting
US03-0
Clearwater, Florida · Recruiting
US05-0
Orlando, Florida · Recruiting
US08-0
Syracuse, New York · Not yet recruiting
US04-0
Irving, Texas · Recruiting
US02-0
San Antonio, Texas · Recruiting
Site AUS01-0
Melbourne, Victoria, Australia · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.